On February 22, 2021, the U.S. Food and Drug Administration (FDA) approved cemiplimab-rwlc for the first-line treatment of advanced non-small cell lung cancer (NSCLC) in patients whose tumors have high PD-L1 expression (tumor proportion score ≥50%), as determined by an FDA-approved test. Patients must either have metastatic or locally advanced tumors that are not candidates for surgical resection or definitive chemoradiation, and the tumors must not have EGFR, ALK, or ROS1 aberrations.
Read the FDA announcement.
Read the Sanofi announcement.
Posted 2/22/2021
From mental health concerns to fertility preservation, adolescents and young adults with cancer require a specialized approach to treatment and survivorship care. In honor of Childhood Cancer Awareness Month, ACCC highlights a pivotal program from the University of North Carolina Lineberger Comprehensive Cancer Center and resources that meet the critical needs of these patients.
